Quan et al. demonstrate that T cells engineered with antibody-T cell receptors (AbTCRs) targeting GPC2 outperform CAR T cells in neuroblastoma, showing improved efficacy due to stronger TCR signaling, greater memory T cell expansion, and increased CD8+ T cell infiltration, offering promising potential for neuroblastoma therapy. This evidence concerns the gene CD8A and neuroblastoma.